End-stage Renal Disease (ESRD) Pilot Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Renal Dialysis

In brief

The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.

Key facts

Study ID
NCT03787368
Run by
Bayer
People needed
55
Starts
2019-01-31
Expected to finish
2021-09-15
Last updated by the study team
2022-03-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.